[
    {
        "utterance": "Jae Sung: Hi everybody. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Emily Balskus: Hi Emily. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Hi. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Emily, it's nice to see you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Emily Balskus: Yeah, nice to see you too. Looks like we're going to do this uh facilitate this one together. ",
        "annotations": {
            "process management": "The speaker is acknowledging the collaborative nature of facilitating the meeting together."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, sounds great. ",
        "annotations": {
            "Supportive response": "The speaker is expressing agreement and a positive evaluation for the facilitation arrangement."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So should we start by going around the room introducing everyone, everyone introducing themselves? ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by suggesting an activity to introduce everyone.",
            "encourage participation": "The speaker is inviting all participants to contribute by introducing themselves."
        }
    },
    {
        "utterance": "Emily Balskus: Yeah, that sounds good. ",
        "annotations": {
            "Supportive response": "Expressing agreement with Rosa Krajmalnik-Brown's suggestion without adding new content."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: You want to start, Emily? ",
        "annotations": {
            "encourage participation": "The speaker is inviting Emily to contribute by starting the introductions.",
            "process management": "The speaker is managing the meeting flow by organizing who will start the introductions."
        }
    },
    {
        "utterance": "Emily Balskus: Yeah, yeah, that'd be great. ",
        "annotations": {
            "Supportive response": "The speaker is expressing agreement and a positive sentiment towards proceeding with the introduction, as suggested by Rosa Krajmalnik-Brown."
        }
    },
    {
        "utterance": "Emily Balskus: Um so I'm Emily Balskus, I'm in the chemistry department at Harvard University. My lab studies gut bacterial metabolism and enzymes and also develops chemical tools to manipulate and study metabolic activities in microbiomes. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise and qualifications related to her work in the chemistry department at Harvard University and her lab's studies."
        }
    },
    {
        "utterance": "Emily Balskus: And yeah, do you want to just sort of have uh each person then, you know, introduce the next person. Okay. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new method for the group to follow, suggesting each person introduces the next one.",
            "process management": "The utterance directly manages the meeting flow by proposing a procedure for introductions."
        }
    },
    {
        "utterance": "Emily Balskus: Yeah, so maybe um uh Will, you could go next. ",
        "annotations": {
            "encourage participation": "The speaker is directly inviting Will to contribute to the conversation by introducing himself.",
            "process management": "The speaker is managing the flow of the meeting by suggesting the order of introductions."
        }
    },
    {
        "utterance": "Will Ludington: Hello, um I'm Will Ludington, I'm at the Carnegie Institution uh and the John Hopkins Biology Department. Um I my lab studies uh gut bacteria in fruit flies and uh think about uh kind of complex uh interactions um in microbial communities. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his own expertise and qualifications related to his lab's work in gut bacteria and microbial communities."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So you lead us to the next person. You tell us who the next person is. ",
        "annotations": {
            "process management": "Rosa Krajmalnik-Brown is managing the meeting flow by suggesting who should go next.",
            "encourage participation": "Rosa Krajmalnik-Brown is encouraging someone to participate by suggesting they introduce the next person."
        }
    },
    {
        "utterance": "Will Ludington: Oh, I choose the next one. Sorry. Um uh Elizabeth. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by selecting and announcing the next person to introduce themselves."
        }
    },
    {
        "utterance": "Will Ludington: Bess is uh next uh on my screen. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by indicating who is next to be introduced."
        }
    },
    {
        "utterance": "Elizabeth Bess: Hi folks. Um I'm Elizabeth, I'm from UC Irvine. I'm in the Department of Chemistry. My uh lab studies the chemical reactions happening in the the gut um by facilitated by bacteria. We're really interested um specifically right now we're really interested in and I'm excited about discussion about metal ions, ionciation, um and also um metabolites that are produced by bacteria and consumed uh by bacteria. ",
        "annotations": {
            "signal expertise": "Elizabeth explicitly states her own and her lab's expertise related to the task, mentioning their study of chemical reactions in the gut facilitated by bacteria and their interest in metal ions, ion speciation, and metabolites."
        }
    },
    {
        "utterance": "Elizabeth Bess: Speak to the next person. ",
        "annotations": {
            "encourage participation": "Elizabeth Bess is inviting the next person to contribute by introducing themselves.",
            "process management": "Elizabeth Bess is managing the meeting flow by organizing the introduction process."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Oh, I'm sorry. Yes. ",
        "annotations": {
            "Supportive Response": "The utterance 'Oh, I'm sorry. Yes.' expresses agreement and a positive acknowledgment of the previous request, fitting the definition of a supportive response."
        }
    },
    {
        "utterance": "Elizabeth Bess: Um uh Linea. ",
        "annotations": {
            "encourage participation": "Elizabeth Bess is inviting Linea to introduce herself, encouraging her participation in the meeting."
        }
    },
    {
        "utterance": "Linnea Freeman: Hi everyone, I'm Linnea Freeman. I'm at Furman University in the Biology Department and the Neuroscience program. Um my lab looks at sex differences in response to consumption of a high fat, high sugar diet. Um we look at the microbiome changes, but um my my area is more in the brain and we look at neuroinflammation. Uh we focus on astrocytes and microglia. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their own expertise and qualifications related to their research area, mentioning their department and research focus."
        }
    },
    {
        "utterance": "Linnea Freeman: Um Lisa. ",
        "annotations": {
            "process management": "The speaker is attempting to manage the meeting flow by transitioning to the next person's introduction."
        }
    },
    {
        "utterance": "Lisa Osborne: Okay, uh I'm at UBC in Vancouver BC Canada. We study uh neuroinflammation in the context of EAE, so a mouse model of MS. We have a germ free facility here and right now most of our studies are focusing on the effect of an aging microbiota, um dietary interventions that can modulate EAE outcomes and how helmets, so these worms that get into the gut, how they influence EAE outcomes and we're particularly interested um in how things that happen in the gut influence CNS resident uh populations and inflammation. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lisa Osborne: So. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lisa Osborne: And I will go to Jay, I think is the next one. ",
        "annotations": {
            "process management": "This code applies because the speaker is managing the meeting flow by indicating who the next person is to introduce themselves."
        }
    },
    {
        "utterance": "Jae Sung: Oh. Thanks Lisa. Um hi everybody, I'm Jay Song. I'm up here in uh uh Mayo Clinic in uh Rochester, Minnesota. Um our group is a computational biology and bioinformatics lab. We take a multi-omics approach to study patients with uh with uh autoimmune disease in particular rheumatoid arthritis and vasculitis. ",
        "annotations": {
            "signal expertise": "Jae Sung explicitly states his group's focus and approach, signaling his expertise in computational biology and bioinformatics."
        }
    },
    {
        "utterance": "Jae Sung: Um so that's kind of more on the clinical and translational side. On the more basic science side, we do uh uh bioinformatics studies um of uh microbial genomes to identify what chemicals, natural products they could be producing and how those uh chemicals could influence uh uh host disease um in the context of autoimmunity. ",
        "annotations": {
            "signal expertise": "Jae Sung explicitly states his own and his lab's expertise in bioinformatics and studying microbial genomes."
        }
    },
    {
        "utterance": "Jae Sung: Um okay, so next I'm going to um send this hot potato to Rosa. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by indicating who should go next.",
            "encourage participation": "The speaker is also inviting Rosa to contribute by passing the responsibility to her."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Thank you for not sending the hot potato earlier because there was vacuuming here in the background. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges Jae Sung's decision not to pass the task to someone else.",
            "express humor": "The utterance makes a joke about 'sending the hot potato' and the reason for not wanting it."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So I appreciate that. ",
        "annotations": {
            "express humor": "Rosa makes a light comment about the 'hot potato' and the background noise, indicating humor.",
            "supportive response": "Rosa positively responds to Jae Sung's consideration of the background noise, showing appreciation."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Uh this is a good time. So I am Rosa Krahnik Brown or Rosie. I'm an environmental engineer by training. Uh but I have been working with the microbiome for the past 13 years, gut microbiome. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise or qualifications related to the task, mentioning her background as an environmental engineer and her 13 years of experience working with the microbiome."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: My my group um uh is interested in um metabolism, how the gut microbiome changes metabolisms and might change um energy extraction by the host, but we also have done a lot of work with autism and the microbiome. And so we look at micro microbe interactions, we look at the environment, of course, and we also look at chemicals, metabolites being produced by these microbes. ",
        "annotations": {
            "signal expertise": "Rosa is explicitly stating her group's expertise and areas of study.",
            "develop idea": "She is elaborating on her group's interests and areas of study, which can be seen as developing the idea of what her group does."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I need to pass it to someone else, of course, and I was forgetting, but I got it. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by attempting to hand over the responsibility of continuing the introductions.",
            "assign task": "The speaker tries to assign the task of continuing the introductions to someone else.",
            "express humor": "The speaker makes a light comment about passing a 'hot potato,' which can be considered humor."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Uh I know Emily was going to remind me. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it does not explicitly engage with the discussion topics in a manner that fits the provided codes."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Uh Pamela. ",
        "annotations": {
            "process management": "Rosa Krajmalnik-Brown is managing the meeting flow by passing the introduction to Pamela."
        }
    },
    {
        "utterance": "Emily Balskus: Hi everyone. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Pamela Chang: Hi everyone. Uh my name is Pam Chang. I'm an assistant professor at Cornell. Uh I'm in the Department of Microbiology and Immunology. I'm trained as a chemical biologist and immunologist and my lab um studies the interactions between the gut microbiota and the host immune system um via small molecule metabolites. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their qualifications and current position, signaling their expertise in the field."
        }
    },
    {
        "utterance": "Pamela Chang: We use mouse models of inflammatory bowel disease and infection. We're interested in the gut brain axis obviously. Um and the other half of my lab works on developing chemical tools to probe the metabolism of the gut microbiota and uh this we're really interested in looking at enzymatic activities carried out by uh bacteria in the gut. ",
        "annotations": {
            "develop idea": "The speaker is expanding on her lab's work, providing details on their research focus, methods, and areas of interest.",
            "signal expertise": "The speaker is explicitly stating her lab's expertise and qualifications in the field of microbiology and immunology."
        }
    },
    {
        "utterance": "Pamela Chang: And then now I'll pick Tom. ",
        "annotations": {
            "process management": "This code applies because Pamela Chang is managing the meeting flow by indicating who will be introduced next."
        }
    },
    {
        "utterance": "Tom Mansell: Hey, that's good. ",
        "annotations": {
            "supportive response": "The utterance expresses a positive sentiment towards something previously said, which aligns with the definition of a supportive response."
        }
    },
    {
        "utterance": "Tom Mansell: I actually went to Cornell for my PhD, so. ",
        "annotations": {
            "signal expertise": "The speaker is implicitly signaling his academic background and potential expertise by mentioning he went to Cornell for his PhD."
        }
    },
    {
        "utterance": "Tom Mansell: Um so uh I'm Tom Mansel, I'm from Iowa State University. I'm in chemical engineering. ",
        "annotations": {
            "signal expertise": "The utterance explicitly states the speaker's field of work, which is chemical engineering, signaling his expertise or background.",
            "None": "No other relevant code applies to this utterance as it is primarily an introduction and a statement of expertise."
        }
    },
    {
        "utterance": "Tom Mansell: And uh our lab focuses on uh our goal is to engineer live biotherapeutics. So uh enabling uh engineered probiotics to secrete small molecules or peptides or proteins that would have a therapeutic effect on the host. ",
        "annotations": {
            "signal expertise": "Tom Mansell is explicitly stating his lab's area of expertise and current work.",
            "clarify goal": "Tom is defining his lab's goal and area of work."
        }
    },
    {
        "utterance": "Tom Mansell: Um and so my goal here is to uh kind of find targets. ",
        "annotations": {
            "clarify goal": "Tom Mansell is defining his goal for the meeting or collaboration by stating what he aims to achieve, which is to find targets."
        }
    },
    {
        "utterance": "Tom Mansell: We focus a lot on the chassis uh right now and so uh my goal is to find small molecule metabolites that would be good to have around or get rid of um and uh so I think this discussion will be good for that. I hope. ",
        "annotations": {
            "clarify goal": "The speaker is defining their goal, which is to find small molecule metabolites that would be good to have around or get rid of, and they see the discussion as beneficial for that purpose."
        }
    },
    {
        "utterance": "Tom Mansell: And I'll throw it to Mark. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by passing the turn to someone else, Mark."
        }
    },
    {
        "utterance": "Mark Mimee: Thanks Tom. ",
        "annotations": {
            "final answer": {
                "acknowledge contribution": "Mark is verbally recognizing Tom's input, even if briefly."
            }
        }
    },
    {
        "utterance": "Mark Mimee: Um so my name is Mark Mimi. I'm an assistant professor at the University of Chicago in the Department of Microbiology and the School of Molecular Engineering. ",
        "annotations": {
            "signal expertise": "Mark explicitly states his position as an assistant professor and his department affiliations, which relates to his expertise."
        }
    },
    {
        "utterance": "Mark Mimee: And my group is essentially uh a synthetic biology microbiome group. So we're really interested. ",
        "annotations": {
            "signal expertise": "Mark is explicitly stating his group's expertise and interest area, signaling his relevance to the topic.",
            "clarify goal": "Mark is defining his group's objectives and focus area, providing clarity on what they are interested in."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: think. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Unidentified Speaker: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Unidentified Speaker: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Will Ludington: Can I start with a question based on reading that question? ",
        "annotations": {
            "ask question": "The speaker is requesting permission to ask a question, which falls under the category of asking for information or clarification."
        }
    },
    {
        "utterance": "Will Ludington: Or a set of questions. ",
        "annotations": {
            "ask question": "The speaker is expressing intent to ask questions, seeking information or clarification."
        }
    },
    {
        "utterance": "Will Ludington: Um, so when I think about like neurons and brain, I think of like when information is transmitted it's through a synapse is like really uh tightly coupled way to control how the information is transmitted. Um, when I think about like microbial community, I don't I mean like I don't know where that synapse is to even get the bacteria signal there was a secretone part in here. Like how does the bacterial signal get sensed in the first place and are the are the like the abundance of these metabolites enough to like stimulate a signal and are there enough channels, specific channels that could sense one of these metabolites that the bacteria would be uh producing or is it more of an aggregate signal uh from the whole community that's being sensed or uh so be able to point out that it might be like specific molecules that are really important. ",
        "annotations": {
            "ask question": "The speaker is requesting information, clarification, or expertise from other team members on how bacterial signals are sensed and the role of metabolites and specific channels.",
            "develop idea": "The speaker is expanding, building upon existing ideas through reasoning and analogy, comparing neuronal signal transmission to microbial community interactions."
        }
    },
    {
        "utterance": "Will Ludington: Um that is the kind of the point of some of the questions in there. And I'm just curious like to hear people's thoughts about you know, is it one thing that's being sensed or is it kind of a profile things being sensed and how is, you know, if it is one thing like how is is there a directed channel for that thing or is it kind of a distributed network? Um is there a synapse or is there a distributed network that's kind of pulling that signal in? ",
        "annotations": {
            "ask question": "The speaker is explicitly requesting information or clarification on how bacterial signals are sensed.",
            "develop idea": "The speaker is also expanding on existing ideas by discussing possible mechanisms of signal sensing."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Does anyone know? ",
        "annotations": {
            "ask question": "Rosa Krajmalnik-Brown is requesting information or expertise from other team members regarding Will Ludington's previous question."
        }
    },
    {
        "utterance": "Pamela Chang: I'll speak to this. ",
        "annotations": {
            "None": "No specific code directly applies as Pamela is simply offering to contribute to the discussion without adding new content or explicitly signaling expertise."
        }
    },
    {
        "utterance": "Pamela Chang: Um, so I think that the field is is taking more of a reductionist approach because it's easier to rack your head around, you know, what one metabolite might do or what one family of metabolites might do. But I think that we really should be thinking systemically. I think you're getting at the question of there's as somebody alluded to earlier, thousands of metabolites and they all if they all have activities, what is the summation of all their activities. ",
        "annotations": {
            "develop idea": "Pamela is expanding on the idea of approaching the study of metabolites by suggesting a shift from a reductionist to a more systemic approach.",
            "ask question": "Pamela poses a question about the summation of activities of all metabolites, implying a request for information or thought on this complex issue."
        }
    },
    {
        "utterance": "Pamela Chang: And so I think that's probably more likely that what's going on in vivo, um, although, you know, I think that we're as a field just coming toward that, um, that question. Uh and I think it's a really interesting one for sure. ",
        "annotations": {
            "supportive response": "Pamela is expressing agreement and a positive evaluation of the discussed idea, showing support for the direction of the field."
        }
    },
    {
        "utterance": "Pamela Chang: But yeah, bottom line, I don't think we know. ",
        "annotations": {
            "identify gap": "The speaker explicitly recognizes a lack of knowledge in the field regarding how bacterial signals are sensed, indicating a gap in current understanding."
        }
    },
    {
        "utterance": "Jae Seungh: Probably all of all of the above will. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or validation with previous contributions without adding new content."
        }
    },
    {
        "utterance": "Jae Seungh: I mean, like there's receptors in the epithelial lining that respond to um particular antagonist or agonist. ",
        "annotations": {
            "develop idea": "Jae Seungh is expanding on the discussion by suggesting a specific mechanism (receptors in the epithelial lining) by which bacterial metabolites can influence the host.",
            "propose new idea": "Jae Seungh introduces a specific idea about receptors in the epithelial lining responding to antagonists or agonists, contributing to the discussion on how bacterial signals are sensed."
        }
    },
    {
        "utterance": "Jae Seungh: Um, microbial produced metabolites could, you know, if you have a leaky gut, they could kind of, you know, the metabolites can find themselves into the circulatory system. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the idea of how microbial-produced metabolites could influence the host by suggesting a pathway through a leaky gut.",
            "offer feedback": "The speaker is providing a perspective on the potential interaction between microbial metabolites and the host's circulatory system."
        }
    },
    {
        "utterance": "Jae Seungh: And who knows what happens after that. Um, you can stimulate the um, kind of the inter endocrine cells to actually make and in turn they make, you know, ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous idea about how microbial metabolites could influence host biology, specifically through the stimulation of inter endocrine cells.",
            "ask question": "The speaker asks a question seeking information or clarification on what happens after the stimulation of inter endocrine cells by microbial metabolites."
        }
    },
    {
        "utterance": "Jae Seungh: different types of hormones um that affect other the activities of different tissues. Um, in regards to synapses at the inter nervous system, definitely um could be one mechanism, but apart from that, there's probably various other ways that microbial products could affect the brain. So complex. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by discussing possible mechanisms of how microbial products could affect the brain.",
            "supportive response": "The speaker is providing a positive and engaging response to the discussion, exploring the complexity of the topic."
        }
    },
    {
        "utterance": "Mark Mimee: Yeah, along those lines, I don't know if anyone knows about more, but ",
        "annotations": {
            "supportive response": "Mark is expressing agreement and willingness to engage with the topic, indicating a supportive stance.",
            "encourage participation": "Mark is inviting others to share their knowledge, encouraging participation in the discussion."
        }
    },
    {
        "utterance": "Mark Mimee: I know there have been stories that describe like um rather serotonin or serotonin producing sorry, serotonin producing microbes or GABA producing or consuming microbes uh like evoking this notion that making or depleting neurotransmitters affects uh the gut brain axis. ",
        "annotations": {
            "develop idea": "Mark is expanding on existing ideas about how microbes producing serotonin or GABA can affect the gut-brain axis.",
            "supportive response": "Mark is expressing a positive evaluation of the notion that microbes can influence the gut-brain axis by affecting neurotransmitter levels."
        }
    },
    {
        "utterance": "Mark Mimee: Has that been shown in different diseases? Like those that microbial activity in the gut to actually affect uh behavior or whatever, you know, neurological phenotype you're looking at. ",
        "annotations": {
            "ask question": "The utterance is a clear request for information on whether microbial activity in the gut affects behavior or neurological phenotypes in different diseases."
        }
    },
    {
        "utterance": "Lisa Osborne: So if I understand your question, you're asking whether or not ",
        "annotations": {
            "ask question": "Lisa Osborne is seeking clarification on Will Ludington's question to ensure she understands it correctly."
        }
    },
    {
        "utterance": "Lisa Osborne: there's been a demonstration of microbial communities impacting biological outcome such as uh behavior. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by acknowledging demonstrations of microbial communities impacting biological outcomes."
        }
    },
    {
        "utterance": "Mark Mimee: Well, more specifically, um by modulating neurotransmitters. Like I I definitely know that there are papers that have shown that like bug makes this neurotransmitter or it can consume this neurotransmitter. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of microbial interaction with neurotransmitters, providing examples from existing research.",
            "supportive response": "The speaker is providing a positive evaluation of existing research on microbes producing or consuming neurotransmitters."
        }
    },
    {
        "utterance": "Mark Mimee: And then there's been suggestions that that metabolic activity within the gut has led to, you know, ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by mentioning suggestions about the link between gut metabolic activity and its effects, building on previous discussions in the conversation."
        }
    },
    {
        "utterance": "Mark Mimee: or will impact the nervous system in some way. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous ideas about the impact of microbial activity on the nervous system, considering how microbial communities might influence neurological outcomes."
        }
    },
    {
        "utterance": "Mark Mimee: Uh but I'm not aware, I'm also not in this field at all, so these studies might be like in the biggest impact journals possible and I'm just completely unaware. ",
        "annotations": {
            "identify gap": "The speaker explicitly states his lack of awareness and not being in the field, indicating a recognition of his own knowledge gap."
        }
    },
    {
        "utterance": "Mark Mimee: Uh I just don't know if uh if that exists. ",
        "annotations": {
            "identify gap": "Mark Mimee is expressing his uncertainty about the existence of studies demonstrating microbial communities impacting biological outcomes by modulating neurotransmitters, indicating a gap in his knowledge or the field's knowledge."
        }
    },
    {
        "utterance": "Will Ludington: Yeah, I always hear the serotonin one and it's like when I've like tried to track that down. ",
        "annotations": {
            "ask question": "The speaker is inquiring about the serotonin topic, indicating a request for information or clarification.",
            "identify gap": "The speaker is expressing difficulty in tracking down information about the serotonin topic, indicating a gap in their knowledge."
        }
    },
    {
        "utterance": "Will Ludington: I never find a a really nice I I never find a really nice solid piece of evidence that supports that. ",
        "annotations": {
            "Critical Response": "Will Ludington is questioning the existence of solid evidence that supports a previously mentioned claim, expressing skepticism.",
            "Ask Question": "The statement implies a request for evidence or clarity on the claim, even though it's phrased as a statement of personal experience."
        }
    },
    {
        "utterance": "Will Ludington: I think that they're like these like metabolomic studies show, hey, it's being produced there. Um, but I haven't found the like, you know, it's like it's also said it's in the um, the smooth muscle uh uh these contractions that a lot of that's just uh very local. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by referencing metabolomic studies and their findings, and discussing their implications.",
            "identify gap": "The speaker implicitly identifies a gap in knowledge regarding direct evidence for certain mechanisms, such as the effect on smooth muscle contractions.",
            "critical response": "The speaker expresses skepticism or uncertainty about the direct impact or evidence for certain claims, indicating a critical response to existing information."
        }
    },
    {
        "utterance": "Will Ludington: Um but the idea that like, yeah, ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Will Ludington: there's a lot of serotonin there, but is it like ",
        "annotations": {
            "ask question": "The speaker is seeking clarification or more information about the role of serotonin in the context of microbial communities and their influence on the host."
        }
    },
    {
        "utterance": "Will Ludington: being used as a neurotransmitter in that case, it might just be a metabolite. ",
        "annotations": {
            "Ask Question": "The speaker is questioning the role of serotonin in the context of gut microbiome interactions with the host nervous system, seeking clarification on its function.",
            "Develop Idea": "The speaker is expanding on previous discussions about microbial metabolites and their potential effects on the host nervous system, specifically regarding neurotransmitters."
        }
    },
    {
        "utterance": "Will Ludington: So I I totally agree and the serotonin is the one I always ",
        "annotations": {
            "Supportive response": "Will Ludington is expressing agreement with a previous statement, showing support for the discussion."
        }
    },
    {
        "utterance": "Will Ludington: like try to track it down, but again, that's not my field, so I would really be curious to know if there is solid evidence for that. ",
        "annotations": {
            "ask question": "The speaker is seeking information about the existence of solid evidence for a claim.",
            "identify gap": "The speaker acknowledges that the topic is not his field, indicating a lack of knowledge."
        }
    },
    {
        "utterance": "Mark Mimee: in a better way. I was wondering like, should we be thinking of common or molecules that are common with the nervous system or should we be looking for completely novel molecules that are, you know, bacterially derived that um are influencing the nervous system in some way that we don't currently know. ",
        "annotations": {
            "ask question": "The speaker is explicitly seeking input or thoughts from others on how to approach the topic of understanding the influence of bacterially derived molecules on the nervous system.",
            "develop idea": "The utterance also subtly contributes to developing the idea by framing the discussion around the types of molecules that could be influencing the nervous system."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I think that's an excellent question because I think there might be molecules that we don't know yet that influence the nervous system. What do you guys think? ",
        "annotations": {
            "ask question": "The speaker is requesting thoughts or opinions from other group members.",
            "encourage participation": "The speaker is inviting others to contribute their thoughts or ideas."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And so I will go back to um, I think it was Will's question about production or consumption by specific microbes. There there is evidence on on mice that specific microbes will change the concentrations at least in the in the system in the blood of certain chemicals or neurotransmitters and not not all of them have been recognized as neurotransmitters. Um, so those might be important too. What are your thoughts? ",
        "annotations": {
            "develop idea": "The utterance expands on an existing idea by providing evidence from mouse studies.",
            "ask question": "The utterance requests thoughts from other team members.",
            "encourage participation": "The utterance invites others to contribute their insights."
        }
    },
    {
        "utterance": "Tom Mansell: also kind of depends probably where it's produced, right? If it's produced near the small intestine, probably has a better chance of getting in the serum. Whereas, you know, in the in the colon, you know, it's probably not as much mass transfer there. ",
        "annotations": {
            "develop idea": "Tom is expanding on the existing idea about microbial product influence by discussing the impact of production location within the gut.",
            "ask question": "Tom's statement implies a question about how location affects the availability and impact of microbial products."
        }
    },
    {
        "utterance": "Tom Mansell: As the chemical engineer, I have to point that out, I guess. That mass transport is a thing. ",
        "annotations": {
            "signal expertise": "Tom Mansell explicitly states his expertise as a chemical engineer to justify his point.",
            "develop idea": "Tom Mansell expands on the discussion about microbial products and their interaction with the host by highlighting the importance of mass transport."
        }
    },
    {
        "utterance": "Tom Mansell: So again, I think people a lot of lots of groups brought up biogeography, but um it's definitely something that we need to keep in mind if we're going to harness these this information in some way is, okay, well, this bacterium produces serotonin, well where and how does it get into the serum if so. ",
        "annotations": {
            "develop idea": "Tom is expanding on previous discussions about biogeography and its implications for bacterial products interacting with the host.",
            "ask question": "Tom is asking for clarification on how bacterial products get into the serum."
        }
    },
    {
        "utterance": "Tom Mansell: And I don't know, you know, you know, there's direct activation of ENS. This is outside of my purview, right? But how would something get to the the brain by the blood brain barrier, I guess? I have to get in the blood first. Right. ",
        "annotations": {
            "code name": "identify gap",
            "explanation": "Tom Mansell recognizes his lack of knowledge on how microbial products could directly activate the ENS and cross the blood-brain barrier."
        }
    },
    {
        "utterance": "Elizabeth Bess: Yeah, I'm interested in what sort of studies people or techniques people think about for tracking um for tracking that. Uh so there's in the 70s and 80s before we were concerned about C14 carbon. There's some beautiful studies that show like the tracking of you know, like pharmacokinetics of drugs, um which we leverage a lot um uh in our lab like going back to use those. When you think about the molecules that are produced endogenously, it does get really tricky to me to think about well even if it's getting produced, where does it go from there? Is it going between cells? Like is it crosses the epithelium is it going through a cell, which could matter in terms of we think a lot about oxidation state. If it goes through a cell, this could change like oxidation state as opposed to between cell. And uh this is something we've struggled with in the lab like thinking about how do you actually track those specific molecules that are getting produced where it's more obvious if it's an exogenous source that you're providing like a carbon, we can use C13 labels too, but how do you do that in vivo um and follow where it goes? And I don't I I I love if someone can answer that or like ideas for how people think about that. ",
        "annotations": {
            "ask question": "The speaker is requesting information on studies or techniques people use for tracking molecules produced endogenously.",
            "identify gap": "The speaker identifies a gap in knowledge regarding how to track endogenously produced molecules in vivo.",
            "encourage participation": "The speaker invites others to share their ideas or techniques for tracking molecules."
        }
    },
    {
        "utterance": "Linnea Freeman: Um, I just wanted to go, sorry, I don't want to interrupt like I can't uh respond to your question, but I was also thinking about what Tom was saying. I think it connects with what you're just saying too and this is so outside of my area, something I want to listen and get information because I have a lot to learn here, but um in terms of crossing the blood brain barrier, that might not be a major like it's certainly a question, but we don't know if there's um small molecules that are traveling that need to get past the blood brain barrier or if for example, we're talking about serotonin activation that's happening in the gut that could then um stimulate the vagus nerve and that would then send a signal to the brain and then, you know, we might not have to get past the blood brain barrier based on who knows if it's a neurotransmitter like dopamine or serotonin produced in the gut. ",
        "annotations": {
            "ask question": "Linnea Freeman is asking a question about the necessity of crossing the blood-brain barrier for microbial products to influence the brain.",
            "develop idea": "She is building upon previous ideas discussed, specifically considering Tom's points and expanding on the concept of how gut microbiota could affect the brain.",
            "identify gap": "Linnea Freeman is highlighting a gap in understanding regarding the mechanisms of influence of gut microbiota on the brain, particularly concerning the role of the blood-brain barrier and alternative pathways."
        }
    },
    {
        "utterance": "Linnea Freeman: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Mark Mimee: Yeah, yeah, one of the techniques that uh or that I I know Michael Fishbach has done a lot of it, but is this idea of using for the defined microbial communities and then doing genetics within the microbes there. So at least there you can envision that if you know microbe A is responsible for the production of this molecule and you can tune that production in a germ free model and then down the line look at that phenotype, you you might depending on whether or not it's also made by the host, you could conceivably track like, okay, the bugs in the gut, it's making this molecule, it's, you know, it's in the serum, it's in the lamina appropriate. Oh, it doesn't make it into the blood brain, so it's not directly acting in those sort of contexts. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea by describing a technique for studying microbial communities and their effects.",
            "offer feedback": "The speaker is providing a specific suggestion or example for approaching the study of how microbes influence the host."
        }
    },
    {
        "utterance": "Mark Mimee: And I think those models are are pretty powerful um although, you know, scaling it to hundreds of molecules and you know, hundreds of different permutations of uh microbial communities makes that a little bit challenging. ",
        "annotations": {
            "Supportive Response": "Mark Mimee expresses agreement and validation by stating that the models are 'pretty powerful'.",
            "Critical Response": "Mark Mimee mentions a challenge with scaling up to hundreds of molecules and permutations of microbial communities, indicating a critical perspective."
        }
    },
    {
        "utterance": "Tom Mansell: Our lab's really interested in the idea of privilege substrates, right? So prebiotics are things that not everybody can eat, right? And ideally there you'd have one that nobody can eat, but your proprietary organism, right? Um, and so uh I really I love the idea of a radio labeled prebiotic such that if you have privilege substrate, it's not going to get converted into dopamine or whatever uh unless that bug uh eats it. ",
        "annotations": {
            "propose new idea": "The utterance introduces a new idea of using radio-labeled prebiotics to study microbial metabolism.",
            "develop idea": "The speaker elaborates on the concepts of privilege substrates and prebiotics, providing a detailed explanation and potential applications."
        }
    },
    {
        "utterance": "Tom Mansell: Yeah, so you'd have to have a sufficiently privileged um substrate to do that. And of course you'd have to make it with C13. ",
        "annotations": {
            "offer feedback": "Tom Mansell is providing specific suggestions for improvement or modification of existing ideas or approaches proposed by other group members.",
            "develop idea": "Tom Mansell is expanding on an existing concept by discussing the requirements and specifics of using privileged substrates and C13 in experiments."
        }
    },
    {
        "utterance": "Emily Balskus: You would need to also know about the actual metabolic pathways in order to to design Right. a substrate, yeah. ",
        "annotations": {
            "Develop idea": "The speaker is building upon previous discussions about tracking molecules and the importance of understanding microbial metabolism.",
            "Offer feedback": "The utterance provides feedback on how to approach the challenge of designing substrates.",
            "Clarify goal": "It clarifies the goal of needing to understand metabolic pathways for designing substrates."
        }
    },
    {
        "utterance": "Tom Mansell: You need to know which bug makes it, right? ",
        "annotations": {
            "offer feedback": "The speaker provides specific feedback on what is needed to move forward with an idea, which is knowing which microbe produces a specific molecule."
        }
    },
    {
        "utterance": "Tom Mansell: And engineer that bug to eat the substrate. Yeah, so that could be the kind of that could be the kind of uh high risk, high reward uh thing we're looking for. ",
        "annotations": {
            "propose new idea": "The utterance introduces a specific approach of engineering a bug to eat a substrate as a potential research direction.",
            "develop idea": "It expands on previous discussions about microbial engineering and interaction with substrates.",
            "signal expertise": "Tom Mansell shares his perspective based on his knowledge in engineering microbes."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, there is a um heavy labeled muffin actually that can be used for clinical trials, but it's a substrate that many microbes will eat. And I I just know this because at some point I was also thinking about like, can we label the microbes, not just the substrate, but the microbes because it goes in their DNA. Um but but that's I'm muffin. I know this because when I started working on the microbiome, I asked John Debase who was um who is my collaborator at the Mayo clinic and uh he said, yeah, there's an isotopic muffin, but the problem is that this is not too specific. So it won't give you that specific prebiotic stimulation that you're looking for. ",
        "annotations": {
            "Signal expertise": "Rosa mentions her experience and collaborators, indicating her expertise.",
            "Identify gap": "Rosa discusses the limitation of the 'isotopic muffin' approach.",
            "Express humor": "Rosa makes a joke about being 'muffin.'"
        }
    },
    {
        "utterance": "Tom Mansell: Right. Right. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement with a previous statement without adding new content."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I think there's also been some studies that have ",
        "annotations": {
            "develop idea": "Rosa Krajmalnik-Brown is expanding on existing ideas by referencing previous studies."
        }
    },
    {
        "utterance": "Elizabeth Bess: um leverage the chemical environment as you're traveling through the GI tract to kind of release things at different pH or in different chemical environments, which doesn't have a lot of that is I mean, the precision is not maybe fabulous there, but um could be a way maybe to get some of these small like a C13 labeled molecule to that location because I think that's a big challenge in studying metabolites that if you are like orally dosing some of the metabolites we study, if we orally dose them, they will be immediately absorbed into systemic circulation, but in real life, um that doesn't happen because they're actually um sort of like what Tom's mentioning like part of something that's more complex that doesn't fully get um like perhaps uh hydrolysis of the glucuronide or something. It doesn't happen until you're in the colon and then it releases in the right spot. Um I don't know. So I I don't want to interrupt the conversation, but I've seen that Sarah is very quiet and um we didn't give her a chance to introduce herself because she had to step out. So Sarah, did you want to do a quick introduction and maybe we can hear from you? ",
        "annotations": {
            "develop idea": "The speaker expands on existing ideas by discussing the chemical environment of the GI tract and the challenges of studying metabolites.",
            "offer feedback": "The speaker provides suggestions for potential approaches to studying metabolites, such as leveraging the chemical environment of the GI tract.",
            "encourage participation": "The utterance invites Sarah to introduce herself and share her thoughts, encouraging participation."
        }
    },
    {
        "utterance": "Sarah MacEachern: Yeah, sorry. I apologize. I've had to do two days, you know what it's like, you know, patients come first every day. Um Um yeah, I'm I'm a developmental fellow um who's just offered an assistant professor position at the University of Calgary. So I'm sort of like in the very, very early stages. Um my plan is to use precision medicine approaches to approach neurodevelopmental conditions to try to understand them better, but my PhD work was in the neuroscience of the gut, which has sort of brought me back around to this question of um, you know, sort of microbiome and neurodevelopmental conditions. I have to be honest with you for most other sessions I've felt I've been able to follow and it's probably because I came a little late, but um sort of the level of the scientific discussion has been a bit above me, which is in part why I haven't jumped in yet. So it's been part of what I've really enjoyed about the is that I truly have learned so much and like my day-to-day I think looks very different from a lot of you. So um I don't have anything to add quite yet other than to say like you guys are so smart. ",
        "annotations": {
            "final answer": {
                "identify gap": "Sarah mentions that the discussion level has been above her, implying a gap in her current knowledge.",
                "express humor": "Sarah makes a light comment about the intelligence of others, expressing humor."
            }
        }
    },
    {
        "utterance": "Jae Sung: You're so smart. Okay. ",
        "annotations": {
            "Supportive Response": "The speaker is expressing agreement and positive evaluation of Sarah's intelligence or capability.",
            "None": "Not applicable as Supportive Response applies."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So I I I just want to make sure you you had an opportunity. So let us know raise your hand. ",
        "annotations": {
            "encourage participation": "Rosa invites others to contribute by raising their hands, ensuring everyone has an opportunity to participate.",
            "process management": "Rosa manages the meeting process by ensuring everyone has a chance to speak."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Maybe maybe maybe you can think about how do we measure these in for ",
        "annotations": {
            "code name": "encourage participation",
            "explanation": "The speaker is inviting others to contribute their thoughts or ideas on a topic, encouraging participation."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: precision medicine actually in humans. So that's one I'm interested in. ",
        "annotations": {
            "Clarify goal": "Rosa Krajmalnik-Brown is expressing her interest in precision medicine approaches in humans, which relates to defining or clarifying objectives for research or discussion."
        }
    },
    {
        "utterance": "Sarah MacEachern: I know that's something I've been wondering about for a while, totally. And worst case I'll just be your guys's hype girl, be like, you know, what's up? ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges the group's discussion and expertise.",
            "express humor": "The speaker uses humor by referring to herself as the group's 'hype girl'.",
            "encourage participation": "The speaker encourages participation by downplaying her expertise and showing willingness to learn."
        }
    },
    {
        "utterance": "Emily Balakus:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance as the utterance is missing."
        }
    },
    {
        "utterance": "Tom Mansell: I think, you know, just to kind of steer the conversation in your direction that, uh, if you, uh, you know, we talk about precision medicine and we thought, okay, well, let's sequence everybody's microbiome and we'll we'll administer a drug based on your microbiome, but, um, what about, you know, the same, not that anybody would have exactly the same microbial composition, right? That would be, uh, very unusual. But like, you know, the same a similar composition might give you totally different phenotypes in a in two hosts, right? And so like maybe there are metabolomic ways of, uh, of doing precision medicine that that where key metabolites are measured and you can say, okay, well, you know, if this person has a lot of build up of X, you know, it means that means something about metabolism of whatever drug of the of the line. Is is that a thing? Um, or are people really focusing on genetics and micro, you know, ",
        "annotations": {
            "develop idea": "Tom Mansell is expanding on existing ideas about precision medicine and microbiome sequencing by suggesting a metabolomic approach.",
            "propose new idea": "Tom introduces the idea of using metabolomic ways for precision medicine, suggesting a new perspective.",
            "ask question": "Tom asks a question about the focus of research, whether on genetics and microbial composition or another approach."
        }
    },
    {
        "utterance": "Jae Sung:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: the first and second genome, let's say as the, um, as the the focus for precision medicine. ",
        "annotations": {
            "develop idea": "This code applies because Tom Mansell is expanding on the concept of precision medicine by mentioning the consideration of both the 'first and second genome', which suggests building upon existing ideas about incorporating microbiome data into medical approaches."
        }
    },
    {
        "utterance": "Mark Mimee: I mean, I think more and more people are looking at the metabolome as as an output for a variety of diseases, either in a targeted way, looking at, you know, other amino acids or short chain fatty acids or bile acids, or there's some efforts to do untargeted metabolomics, but obviously that's really difficult and at least in clinical trials that are starting to get more and more integrated because there's been this appreciation that yeah, knowing the catalog of the bugs that's there is maybe a little bit predictive of what's going on, but it definitely doesn't, uh, show the full picture. So looking at the transcriptional profile or the metabolomic profile, that might be a little bit more informative for, uh, for what's occurring. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of using metabolomic profiles as an output for disease study, discussing its potential benefits over other methods.",
            "identify gap": "The speaker mentions that current methods do not show the full picture, implying a gap in understanding.",
            "supportive response": "The speaker agrees with the general direction of research and suggests an alternative approach."
        }
    },
    {
        "utterance": "Tom Mansell: How do we determine what what are the ones we need to look at? ",
        "annotations": {
            "Ask Question": "The speaker is requesting information on how to determine which metabolites or molecules are significant to study, indicating a need for clarification or methodology."
        }
    },
    {
        "utterance": "Mark Mimee: Is it metabol, right? Yeah. ",
        "annotations": {
            "ask question": "Mark Mimee starts with 'Is it metabol, right?' which is a query seeking confirmation or clarification."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, just like Emily said, we need to know what you're looking for, right? You need to know the pathways. ",
        "annotations": {
            "develop idea": "Rosa is elaborating on a point made by Emily, emphasizing the importance of knowing the pathways.",
            "supportive response": "Rosa is expressing agreement and support for Emily's point."
        }
    },
    {
        "utterance": "Emily Balakus: Yeah, and just to because I think there's kind of two themes in the prompts of kind of discovery and then there's a a mention of the specific kind of neuroendocrine signals like uh neurotransmitters. And so there's kind of we're at different levels of our understanding I think when we sort of consider those two, you know, prompts. ",
        "annotations": {
            "Develop idea": "The speaker is expanding on the existing ideas and conversation by highlighting two themes and their implications.",
            "Summarize conversation": "The speaker is reflecting on the conversation and themes discussed."
        }
    },
    {
        "utterance": "Jae Sung: Tom, did we answer your question about pharmaceutical drugs? You mentioned something about pharmaceutical drugs, right? ",
        "annotations": {
            "ask question": "Jae Sung is asking for clarification on whether Tom's question about pharmaceutical drugs was answered."
        }
    },
    {
        "utterance": "Tom Mansell: Oh, well, I just thinking of precision medicine in terms of, uh, you know, dosing or administering particular drugs to a patient. ",
        "annotations": {
            "clarify goal": "The speaker is discussing his perspective on precision medicine, specifically in terms of drug dosing and administration, which helps clarify the goals or considerations in this field."
        }
    },
    {
        "utterance": "Tom Mansell: Um, can you use the gut metabolome or the serum metabolome to, uh, make decisions about that, about, you know, uh, liver activity or, uh, you know, uh, those kinds of things. But, you know, in in microbial context, I'm not sure that okay, we used your microbiome and we determined that we should give you this drug. I don't think that that's just using the microbiome is a good probably going to be a good predictor. ",
        "annotations": {
            "ask question": "The speaker is asking a question about using the gut or serum metabolome for decision-making in drug administration.",
            "critical response": "The speaker is expressing a concern or questioning the approach of using the microbiome alone for predicting drug administration."
        }
    },
    {
        "utterance": "Will Ludington: Another question, um, kind of I think related to all of this is, um, if there's some signal that's being transmitted from the gut to the brain, like how close is it to saturation? So like if could we do an experiment where we added more of the, you know, the ligand and then we see would it go would whatever we're measuring would it go up or are we basically like a normal person is always saturated and it's only these cases where we get some kind of depletion, something's wrong where where we see an effect. ",
        "annotations": {
            "ask question": "The utterance is a clear request for information about the saturation level of a signal from the gut to the brain and how it might be experimentally tested.",
            "develop idea": "The question builds upon previous ideas discussed in the conversation, exploring the concept of signal saturation in the context of gut-brain communication."
        }
    },
    {
        "utterance": "Elizabeth Bess:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Will Ludington: In which case, you know, there's certain kind of studies that that we're limited to, you know, what we can do. So if and we'd have to do deletion experiments and then the deletion experiments seem like they're really hard. Mark was talking about like using fage, um, but then again that's like you have to design a fage for each species. Um, is it like could we, you know, do like kind of combinatorial like chemical libraries, uh, like just go straight to the metabolites or is there like I think Jay talked about like is there a list, a prioritized list of metabolites, um, that we could kind of come up with, um, that we could kind of add in more and see, you know, give each one to see if it changes our output or is it like or is there a way chemically to deplete certain things like you design an enzyme to break, um, whatever metabolite you're looking for, I don't know. ",
        "annotations": {
            "ask question": "The speaker is asking a question about experimental approaches and methods for studying metabolites and their effects."
        }
    },
    {
        "utterance": "Tom Mansell: pharmacodynamics basically versus, you know, most people talk about pharmacokinetics, right? But pharmacodynamics is just important. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Yeah, I think I think that that's a this looks like a job for live, uh, you know, live bacteria in there that would be secreting enzymes that I mean, yeah, you can probably deliver enzymes with certain, uh, uh, world delivery mechanisms, but, you know, supplying different levels of, for example, serotonin or whatever, uh, you can just that this sounds well to me, every, you know, I have a hammer, right? Uh, and this looks like something I can hit with it, uh, you know, in terms of synthetic biology, you can design different promoters that would make different amounts of serotonin and then I I I really like that. ",
        "annotations": {
            "propose new idea": "The speaker proposes using live bacteria to secrete enzymes and designing promoters to control serotonin production as a new approach.",
            "develop idea": "The speaker elaborates on the proposed idea, discussing its potential implementation through synthetic biology.",
            "offer feedback": "The speaker provides a positive response to the idea, suggesting it aligns with his perspective on synthetic biology."
        }
    },
    {
        "utterance": "Tom Mansell: Uh, that that point of view though in terms of saturation because yeah, you can make all the serotonin you want, but if it's already saturated, who cares, right? ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of serotonin production in the context of gut microbiome and its saturation levels.",
            "critical response": "The speaker is questioning the utility of producing serotonin if the system is already saturated."
        }
    },
    {
        "utterance": "Tom Mansell: Um, yeah, I really like that, uh, um, approach. ",
        "annotations": {
            "Supportive Response": "Expressing agreement or positive evaluation for an approach mentioned by another group member."
        }
    },
    {
        "utterance": "Tom Mansell: But yeah, that's that's certainly something that I can look into it. And and you know, there there are, um, very bugs out there that are engineered, for example, to screen enzymes to get rid of build up of phenyline, um, and uh, oxalic acid and hyper ammonia, right? ",
        "annotations": {
            "develop idea": "The speaker expands on existing ideas by providing specific examples of engineered bugs.",
            "signal expertise": "The speaker demonstrates knowledge about engineered bugs, indicating expertise.",
            "supportive response": "The utterance is supportive, providing additional information to the discussion."
        }
    },
    {
        "utterance": "Tom Mansell: Uh in the gut, um, those are in clinical trials right now. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Um, not mine, but uh. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Will Ludington:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Pamela Changi: Another crude way to get back on into the linear range is to treat with antibiotics. And then if you can eliminate, if you know which bacteria are making the metabolites of interest, you can then knock down the level and then and then rescue. Um, and then and then you wouldn't be saturated anymore. But it's quite possible a lot of the metabolites are saturating at the steady state. ",
        "annotations": {
            "offer feedback": "Providing a specific methodological suggestion for experimentally approaching the study of metabolites.",
            "develop idea": "Building upon the existing discussion about studying microbial effects on metabolites by suggesting a method to knock down and rescue metabolite levels."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So I I want to steer the pot a little bit and say that, um, I've heard great comments about, um, neurotransmitters, metabolites and I can say maybe small molecules, but no one had said anything about metal ions. And I see that that is a title in our topic. So anyone has something you would like to share about metal ions? ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by steering the conversation towards a specific topic (metal ions) that is on the agenda but hasn't been discussed yet.",
            "identify gap": "The speaker identifies a gap in the conversation by noting that metal ions, despite being a topic of interest, have not been mentioned."
        }
    },
    {
        "utterance": "Elizabeth Bess: I love metal ions. So, um, I I'm excited to see that in the last couple of years that there's been um an increasing appreciation in the literature for the importance of measuring redox potential of the microbiome. ",
        "annotations": {
            "supportive response": "Expressing a positive sentiment towards research on metal ions and redox potential."
        }
    },
    {
        "utterance": "Elizabeth Bess: and also the difficulty of measuring this. Um, that is, uh, when, um, there have been studies about redox potential in microbial communities for decades, but there's also a huge body of literature that talks about how hard it is to have reproducibility across experiments. So like if you have a redox potential measured in one study, it's probably reasonable to be consistent within a study, but across studies, the numbers that they change by like or like orders of magnitude of 10 or 100, um, that are, um, that are dramatic. And one of the things that, um, I'm interested in if anyone has comments on this is, um, how can we measure metal ions better in the gut and in real time? And this has been a huge challenge in the chemical biology field. ",
        "annotations": {
            "identify gap": "The speaker highlights the difficulty in measuring redox potential and metal ions in microbial communities, noting the lack of reproducibility across experiments.",
            "ask question": "The speaker explicitly asks for comments on how to measure metal ions better in the gut and in real time.",
            "encourage participation": "The speaker invites others to share their thoughts on improving the measurement of metal ions."
        }
    },
    {
        "utterance": "Elizabeth Bess: Um, this is really hard with iron, um, in in the like in a complex system, um, where we are is like synchotron is the only way you can actually measure, um, iron speciation as far as I know right now, um, in, um, biological systems. ",
        "annotations": {
            "identify gap": "The speaker explicitly identifies a gap in the ability to easily measure iron speciation in biological systems.",
            "develop idea": "The utterance elaborates on the challenge of measuring iron in complex biological systems, specifying the difficulty with current methods."
        }
    },
    {
        "utterance": "Elizabeth Bess: So it's like doable, but it's not does anybody know how to use one? I don't. I know you can like get time on these, but um it's really complicated. ",
        "annotations": {
            "ask question": "The speaker asks for information about using a synchotron, indicating a request for expertise or knowledge.",
            "develop idea": "The speaker elaborates on the challenges of measuring metal ions, specifically mentioning the difficulty and complexity of using synchotron technology.",
            "identify gap": "The speaker highlights a gap in knowledge or capability regarding the use of synchotron technology for measuring metal ions in biological systems."
        }
    },
    {
        "utterance": "Elizabeth Bess: And so it would be um interesting to think about ways to be able to better measure speciation in vivo. You can do this in some ways with like sealgans, there are probes that work to measure iron three specifically in sealgans in a live context. ",
        "annotations": {
            "identify gap": "The speaker explicitly recognizes the methodological gap in measuring metal ions (speciation) in vivo.",
            "develop idea": "The speaker develops the idea by suggesting the use of sealgans as a potential method for measuring speciation.",
            "offer feedback": "The speaker offers feedback by providing a specific suggestion (using sealgans) to address the challenge of measuring metal ions in vivo."
        }
    },
    {
        "utterance": "Elizabeth Bess:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jae Sung: Elizabeth, um, ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jae Sung: do you do you know if um micro microbes uh they secrete like siderophores? ",
        "annotations": {
            "ask question": "The speaker is requesting information about whether microbes secrete siderophores, making this an explicit question seeking knowledge."
        }
    },
    {
        "utterance": "Jae-Sung Moon: in the in the gut in in the gut environment. I know it happens in soil, but like is there a lot of insoluble iron in the gut that microbes can kind of sense and be like, hey, I'm going to send out these siderophores to mine for us. Does that happen? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on whether microbes can sense insoluble iron in the gut and produce siderophores.",
            "develop idea": "The question expands on known concepts (siderophores in soil) by inquiring about their relevance or occurrence in the gut environment."
        }
    },
    {
        "utterance": "Elizabeth Bess: Yeah, yes. So what the the thought is is we make an assumption in the field that iron is mostly in the reduced state in the gut because the gut is a reducing environment, but um, but there are times when there is more iron three oxidized form, which can happen through inflammation, um, through you know, production of Ross or nitric oxide species. Um, but yeah, bacteria do secrete siderophores in uh the the microbiome. The human also secretes enzymes to capture uh iron three, reduce it to iron two so that it can be brought inside of cells. But I think we have a poor understanding of the dynamics of that. Um, how much of the iron is three versus two. I also fascinated that we have that the body it's the iron is so valuable as you know, as we know, for so many processes that there's no way for the body to um, the body doesn't regulate iron levels except for excretion through stool. That's its only way to get like rid of it. Um, and it's um, but we don't understand really the dynamics of what's happening there and um what the the yeah, oxidation states are and how this changes with dysbiosis of a microbiome. Um, what does this mean at like an uh metal a metal level specifically iron is what what I'm you know wonder about. ",
        "annotations": {
            "develop idea": "Elizabeth Bess is expanding on existing ideas about iron metabolism and its dynamics in the gut.",
            "identify gap": "She highlights the lack of understanding about iron dynamics, specifically its oxidation states and changes with dysbiosis.",
            "ask question": "Elizabeth Bess asks a question about the implications of this at a metal level."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And what does it mean for gut brain communication too, right. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous ideas about the implications of certain factors on gut-brain communication.",
            "encourage participation": "By posing a reflective question, the speaker invites others to consider and discuss the implications for gut-brain communication."
        }
    },
    {
        "utterance": "Elizabeth Bess: Right. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges a prior statement, showing recognition of another group member's input."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Any other thoughts? That was amazing. Thank you, Elizabeth. That was fascinating. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges and thanks Elizabeth for her input.",
            "encourage participation": "The speaker invites others to share their thoughts with 'Any other thoughts?'."
        }
    },
    {
        "utterance": "Emily Baleikus: Maybe to give people just a little bit of a time uh update. I think we have about 20 minutes left. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by providing an update on the time remaining."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So I think in five minutes we should start summarizing. ",
        "annotations": {
            "process management": "The speaker is suggesting a specific time to start summarizing the meeting, which involves managing the meeting flow and time."
        }
    },
    {
        "utterance": "Tom Mansell: Just on the topic of metal ions here. Um, I uh one thing I wrote down was and this is probably pretty wacky. Um, but uh can you spoof like so some so I'm thinking of of PCR, right? When you do PCR, most of us probably at least have done PCR at least I think. Uh, you use magnesium, but if you spoof in manganese, you screw up the polymerase and it gets error prone, right? Can if you substitute or or or put in like some cobalt or something, uh, you know, in the in the microbiome, I wonder how that would change I'm not saying we don't those people with heavy metals, right? But like uh, you know, something a related uh cat ion, right? It's not like iron probably doesn't have a good um ",
        "annotations": {
            "propose new idea": "The speaker introduces a hypothetical scenario about substituting metal ions in the microbiome, similar to how PCR is affected by different ions.",
            "ask question": "The speaker explicitly asks if substituting certain metal ions could change the microbiome."
        }
    },
    {
        "utterance": "Elizabeth Bess: Gallium. Gallium. Okay, yeah. I don't know about that. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: That sounds interesting. ",
        "annotations": {
            "Supportive response": "Tom Mansell is expressing agreement or interest in the previous discussion, which aligns with the definition of a supportive response."
        }
    },
    {
        "utterance": "Elizabeth Bess: There's actually a drug. The um there's a drug that's called Gamite, I think. It's gallium nitrate um that is used it um uh is a really good mimic like um chemically for iron. It doesn't have the same redox properties, but it kind of um it binds to enzymes in a similar way that iron does. ",
        "annotations": {
            "signal expertise": "Elizabeth Bess is explicitly stating her own expertise by sharing specific knowledge about a drug called Gamite and its biochemical properties in relation to iron."
        }
    },
    {
        "utterance": "Tom Mansell: Like just what what would be the if you replaced an animal's iron intake with a little bit of gallium, what would that effect be on the microbiome? ",
        "annotations": {
            "propose new idea": "The speaker proposes a hypothetical scenario to explore the effect of replacing an animal's iron intake with gallium on the microbiome.",
            "ask question": "The speaker is requesting information or insights into the potential effects of gallium on the microbiome in a hypothetical scenario."
        }
    },
    {
        "utterance": "Emily Baleikus: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: I mean that would probably huge, right? I mean one of the things we work with is E coli Nissle and E coli Nissle is a form of E coli that is probiotic. ",
        "annotations": {
            "develop idea": "Tom Mansell is expanding on the previous discussion by providing a specific example from his work, mentioning E coli Nissle as a probiotic form of E coli they work with."
        }
    },
    {
        "utterance": "Tom Mansell: You know, just like anything you would go to the store and buy as probiotic. So probably not super good for you, but you can still tolerate it. Uh, but anyway, it's E coli and it it it makes a lot of one of its differences between that and like lab E coli or pathogenic E coli is iron transport. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the characteristics of E coli Nissle, specifically mentioning its differences from lab E coli or pathogenic E coli in terms of iron transport."
        }
    },
    {
        "utterance": "Tom Mansell: Uh and siderophore production. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: So like it transports iron like crazy and in doing so takes over the E coli and Shigella on Shiga toxin producing E coli niche. So, um like that that to me seems like a great like interface, right? ",
        "annotations": {
            "Develop idea": "Tom Mansell is expanding on an existing idea by providing a specific example of how E. coli Nissle works.",
            "Supportive response": "He is expressing a positive evaluation of the concept.",
            "Signal expertise": "Tom Mansell is sharing his understanding based on his knowledge, which could be seen as signaling his expertise."
        }
    },
    {
        "utterance": "Emily Baleikus: And so cool. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Emily Baleikus: One other quick metal fact that I found really interesting is that if you like look into the defects that germ free mice have, um, impaired metal homeostasis is actually a really big thing. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the topic of metal ions by sharing a fact about germ-free mice and metal homeostasis.",
            "supportive response": "The utterance supports the conversation by adding relevant information."
        }
    },
    {
        "utterance": "Emily Baleikus: Like they have problems with metal uptake. Uh, and I'm not really sure that we understand why. So I think there's a lot of a lot of interesting metal chemistry potentially going on in the microbiome that we just we don't understand. ",
        "annotations": {
            "identify gap": "The speaker explicitly recognizes a lack of understanding about metal uptake in germ-free mice and suggests unexplored aspects of metal chemistry in the microbiome."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I think I would summarize the the the the metal scenario as uh what Elizabeth mentioned for um redox uh conditions or electron acceptors. I think that's um a way to think about it and as um uh enzyme cofactors. ",
        "annotations": {
            "summarize conversation": "The speaker summarizes the conversation about metal ions, referencing previous points made about redox conditions, electron acceptors, and enzyme cofactors."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So there's two different categories that these metals are really needed for those two things. ",
        "annotations": {
            "summarize conversation": "The speaker summarizes the discussion on the roles of metals, categorizing them into two different needs."
        }
    },
    {
        "utterance": "Tom Mansell: So what's needed according to Elizabeth, I guess in this field or this sub sub sub area is um uh really good sensors or or for in vivo metal content, not only by element or ion type, but by species of that element, right? So Elizabeth if you had an iron three versus iron two sensor that would would give you a read out in vivo in in feces that would be pretty cool. ",
        "annotations": {
            "develop idea": "Tom Mansell is building upon Elizabeth's idea about the need for better sensors for measuring metal content.",
            "ask question": "Tom Mansell is asking for a hypothetical scenario or specification of a tool (a sensor for iron three versus iron two).",
            "identify gap": "Tom Mansell explicitly mentions the need for better sensors for in vivo metal content, identifying a gap in current capabilities."
        }
    },
    {
        "utterance": "Elizabeth Bess: I would be so happy. Yes. Yes, that would um yeah, I think that is I think many people would be so happy. But specifically for iron three and not activated by iron two or any other trivalent. ",
        "annotations": {
            "Supportive Response": "Elizabeth expresses her happiness and agreement with the idea of developing a sensor for iron three.",
            "Develop Idea": "She further develops the idea by specifying the requirements for the sensor, specifically for iron three and not activated by iron two or any other trivalent."
        }
    },
    {
        "utterance": "Tom Mansell: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lisa Osborne: Sure. Uh I I'm trying to put them onto the sorry, I'm just trying to find the right button here. ",
        "annotations": {
            "None": "The utterance is a brief acknowledgment with a technical difficulty report, not explicitly covered by the other codes."
        }
    },
    {
        "utterance": "Lisa Osborne: Just trying to get my notes from here onto um our actual slide here. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lisa Osborne: So so far what I've got is I heard a lot about sort of known knowns or known unknowns versus unknown unknowns. Let's get that together. So whether or not um there's benefit to looking at targeted versus untargeted metabolomics and if you do have a candidate that you're interested in like really following the mechanism of how this metabolite is getting across the blood brain barrier acting locally on a Vegas nerve, um what it might be doing to the gut, which cell types might be interacting with or the opposite approach of just like this is everything that exists and they happen to be different. The metabolite black box is different in a disease state versus a healthy state. And so that means that there is something going on and then what are the next steps for characterizing and understanding what those differences mean. ",
        "annotations": {
            "Develop idea": "Lisa is building upon previous discussions by suggesting ways to approach the study of metabolites.",
            "Ask question": "She is asking questions about the approach to studying metabolites.",
            "Summarize conversation": "She is summarizing her understanding of the discussion."
        }
    },
    {
        "utterance": "Lisa Osborne: getting the rest of this over here. Uh, there was a good conversation about tracking these metabolites and so different approaches to doing that. Um, C13 labeling, like I think it was Elizabeth was saying it's really easy if you know what candidate you're looking at, you can make a C13 label and then you can follow that in the gut, in the tissues all the way up to the brain if that's what you're interested in. But if you don't want to provide an exogenous signal, how do you get how do you have that same tracking capability? And so there was this discussion of genetically tractable microbes, either under or over expressing something or using these privileged substrates and whether or not we can I think the the idea was labeling the substrate and then following that through the bug and then through the host, is that right? ",
        "annotations": {
            "ask question": "The speaker is asking about methodological approaches for tracking metabolites, specifically how to have the same tracking capability without providing an exogenous signal.",
            "summarize conversation": "The speaker is summarizing previous discussion elements regarding tracking metabolites, including C13 labeling and using genetically tractable microbes."
        }
    },
    {
        "utterance": "Elizabeth Bess: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, I think the idea was following the metabolites produced by the by the either the micro or the host that will be labeled because they come from that substrate. ",
        "annotations": {
            "Develop idea": "The speaker is expanding on a previous idea about tracking metabolites produced by microbes or hosts.",
            "Supportive response": "The speaker is showing agreement or positive evaluation of previous contributions."
        }
    },
    {
        "utterance": "Lisa Osborne: Yes. Okay. Um, and then even targeted ways of getting that substrate to a certain area. So I guess the idea would be like if you know that a microbe lives in the small versus the large intestine, depending on pH or osmolality or some other physical signal, that substrate could be released in an area where the microbe of interest would be able to have access to it. Again, is that an accurate reflection of what was being said? ",
        "annotations": {
            "summarize conversation": "Lisa Osborne is summarizing her understanding of the discussion about using targeted approaches to deliver substrates to specific microbial populations.",
            "ask question": "Lisa Osborne ends her statement with a question, seeking confirmation if her understanding accurately reflects what was previously discussed."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I think so. I think Tom also mentioned that if we could um identify a specific substrate that will stimulate a very specific microbe then, right? Is that what you said, Tom? ",
        "annotations": {
            "ask question": "The utterance is a clear example of asking for clarification or confirmation on a previous statement made by another group member.",
            "encourage participation": "The utterance also invites Tom to participate in the discussion by seeking his confirmation."
        }
    },
    {
        "utterance": "Tom Mansell: Right. Um, and it could be that you you may have to artificially create that. But yeah. I'm sure there's you know, certain things that I mean fiber, right? Fiber is good for you, probably leads to other things besides. ",
        "annotations": {
            "Develop idea": "Tom Mansell is expanding on the idea of creating specific substrates by mentioning fiber as a beneficial substance.",
            "Supportive response": "Tom Mansell is expressing agreement with the idea of creating specific substrates.",
            "Offer feedback": "Tom Mansell provides an example (fiber) that could be useful for creating specific substrates."
        }
    },
    {
        "utterance": "Lisa Osborne: Um, and then this was a really interesting bit, the value of measuring these levels of metabolites. Um, so even if you measure that there's a difference, say between again like a healthy versus a disease state, what is the impact of that? So you know you have a difference, but is the disease state say if it's got a reduced level of short chain fatty acids in the circulation, is that still saturation for that that person? Um, and is there a way that we can overcome that uh or would the way that we deliver said drug, if it's a short chain fatty acid for example, if we just feed that into the diet versus uh changing the microbiota so that we increase short chain fatty acid capability from the from the microbiota itself, does does that have an effect on the pharmacodynamics of the drug's ability or access to a different tissue site. Um, and then finally, this conversation about metal ions, there's a lot that sort of was happening while I was trying to get these notes um together, but it sounded like ultimately really there are indications that the microbiota has something to do with uh heavy metal metabolism. There's a lot that we don't understand and technically we don't we don't understand it because there are so many technical challenges just in terms of measurement, reporting across studies and one thing that could really advance the field here would be sensors for metal content and species uh in vivo in real time and then within that looking for whether or not these heavy metals are acting as electron acceptors or versus enzyme cofactors. How do we feel about this? ",
        "annotations": {
            "encourage participation": "The speaker invites others to share their thoughts with 'How do we feel about this?'"
        }
    },
    {
        "utterance": "Elizabeth Bess: Good. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or validation to a prior statement."
        }
    },
    {
        "utterance": "Jae Seungh: Very well uh transcribed. ",
        "annotations": {
            "acknowledge contribution": "Jae Seungh is verbally recognizing the effort put into transcribing the conversation.",
            "supportive response": "Jae Seungh is expressing a positive sentiment towards the transcription."
        }
    },
    {
        "utterance": "Lisa Osborne: Okay. Um, I am going to stop sharing and mute myself again and just continue adding, but if you guys want to just continue discussing, I'll try and oh sorry, Sarah, I misspelled your name on that. Um, I'll just keep doing this. Uh, any of you guys want to chat, I'll try and add whatever I can as you as you go. ",
        "annotations": {
            "process management": "Lisa Osborne is managing the discussion by stating she will stop sharing, mute herself, and continue adding information as the discussion goes on."
        }
    },
    {
        "utterance": "Elizabeth Bess: I can do that if you would like a break. But if you want to do it, go for it. ",
        "annotations": {
            "Supportive response": "Elizabeth Bess is expressing agreement and willingness to take on a task, showing support to the group.",
            "Encourage participation": "By saying 'go for it,' Elizabeth Bess is encouraging others to participate or take on the task if they prefer."
        }
    },
    {
        "utterance": "Lisa Osborne: Uh, no, if you want to if you want to do it, absolutely happy. I mean you had a lot to to add to the discussion, so I think you're a good represent representative for us. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges and appreciates another participant's contributions to the discussion.",
            "supportive response": "The speaker expresses agreement and positive evaluation for another group member's role in the discussion."
        }
    },
    {
        "utterance": "Elizabeth Bess: Happy to do it. Thanks for all the good note taking. ",
        "annotations": {
            "supportive response": "The speaker expresses agreement and positive evaluation for another group member's contribution, specifically thanking them for their note-taking effort."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's great. Uh, Lisa, remember we only have one one slide. Yeah. Let's stick to one slide. ",
        "annotations": {
            "process management": "The speaker is directing the meeting flow by reminding participants to limit their presentation to one slide."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And just um highlights salient points. ",
        "annotations": {
            "summarize conversation": "Rosa Krajmalnik-Brown is suggesting to highlight salient points from their discussion.",
            "process management": "Rosa Krajmalnik-Brown is managing the discussion by suggesting what to focus on."
        }
    },
    {
        "utterance": "Mark Mimee: Yeah, I thought I'd bring up in the last couple minutes. Um, I know there's um uh work that's at least gone on in the sort of synbio microbiome space of using engineered bugs as kind of metabolic sinks within the microbiome. So not necessarily caring about their natural activity whatsoever, uh but the two examples that were in PKU where there's accumulation of phenyllalanine and as well as in hyperammonemia, kind of the idea of engineering bugs to scavenge those since they are circulated through the gut. Um, and it's kind of very indirect. They are um associated with neurological diseases. Um, but they're not necessarily associated with the microbiome, but it's at least another thought of maybe we don't even need to understand really what's going on and really just use the microbiome as an agent through which we could engineer the metabolome of the host provided these molecules are, you know, going through inter circulation and that's something. ",
        "annotations": {
            "propose new idea": "Mark Mimee introduces a new concept of using engineered bugs as metabolic sinks within the microbiome.",
            "develop idea": "Mark Mimee elaborates on the idea by providing specific examples and explanations of how it could work."
        }
    },
    {
        "utterance": "Tom Mansell: Elizabeth, I know you're busy, but is is iron three more of an indicator of disease or is the fact that there is that species around, is that what actually serves as a catalyst for um you know, is it is it causal or correlative that the iron three is around during certain disease states? ",
        "annotations": {
            "Ask Question": "Requesting information or clarification on the role of iron three in disease states.",
            "Critical Response": "Questioning the nature of iron three's association with disease states, whether it is an indicator, catalyst, or correlative."
        }
    },
    {
        "utterance": "Elizabeth Bess: Um, I would say there's an element of both. Uh, I think that we think that there's a increase as a field we think there's, you know, an increase in iron three is a consequence of uh inflammation of Ross, but I think that we're also seeing in a few interesting contexts of um there was a paper in E life 2018 ish. Um, that uh from Warren Stevens group uh where they uh gave mice antibiotics and they see differences in redox potential. Um, and it would be uh interesting to see like how does that actually change ironciation as a consequence of of antibiotics as well and what sort of readouts does this end up um or impacts does this end up having on the the activity of them bacteria just because now as I think you had mentioned or um I mean was Jay like uh umphores, like now maybe that we have iron three bacteria producing morephores. Um, which could also induce I think more pathogenicity as well. Um, when there's more iron three around, which has been seen in other contexts. ",
        "annotations": {
            "Develop idea": "The speaker is expanding on existing ideas by discussing the dynamics of iron three in the microbiome, its relation to inflammation, and potential impacts on bacterial behavior.",
            "Identify gap": "The utterance implies a recognition of gaps in understanding the dynamics of iron in the microbiome.",
            "Offer feedback": "By suggesting potential avenues for investigation, such as studying the impact of antibiotics on iron speciation."
        }
    },
    {
        "utterance": "Tom Mansell: Some antibiotics arephores. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Elizabeth Bess: Yep. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Right shuttles. ",
        "annotations": {
            "None": "No relevant code clearly applies to this utterance as it is too ambiguous and does not explicitly convey a clear action, idea, or response that matches the provided codes."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Right, shuttles. You have shuttles also. You have molecules that are shuttles. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the concept of molecules acting as shuttles, building upon previous discussion."
        }
    },
    {
        "utterance": "Mark Mimee: the concern there is like it's fine for the person, but after they excrete it then where does it go? And that's where the EPA gets in and that's where the concerns uh really are. And also for the ethical dilemma of like, well, you could spread a microbiome from one person to another if you're in the same household. And even if person A is sick and is perfectly fine with eating an engineered bug, but you know, their brother or sister or spouse or kid is not and it transfers to them, then they've been unknowingly dosed with a drug. So there's definitely some ethical um issue there. But regardless, it seems like, you know, they're trying to grapple with the the ethics both on the environmental and the medical side of that and it's all moving forward uh at least from my opinion. It's not something it's something that should be figured out and not something that should be necessarily a bar to the field in general. ",
        "annotations": {
            "supportive response": "Mark is also providing a considered response that engages with the potential issues and future directions of the field, showing support for discussing and resolving these concerns."
        }
    },
    {
        "utterance": "Jae Sung: Thank you. Mark on that line like, I mean, this is this is probably related to your your line of work, but is there uh companies that are engineering, you know, bugs and and actually doing clinical trials like for particular diseases? ",
        "annotations": {
            "ask question": "The speaker is requesting information about companies that are engineering bugs and doing clinical trials for particular diseases."
        }
    },
    {
        "utterance": "Mark Mimee: Yeah. Yeah, so the furthest yeah, there's a couple of them. Um so there's definitely folks in the cancer space that have been doing it for a really long time. Uh there's one company that was uh I I mean active biotics. I think it's been acquired by a bunch of different people so I don't even know what it's called anymore. And there's another one based in Boston uh called Synlogic. Um these are all in like phase two trials, all orally dosed. I know some folks that worked at Synlogic and their clinical trial was giving people a half a liter of bacterial culture at a concentration of like 10 to the 11 CFU per mill. And that was approved by the FDA. So it's like really high dosing of bugs going into people um and they've had good phase two results I think or phase 1A phase 1B sorry, phase two results and they're moving forward from there. So ",
        "annotations": {
            "supportive response": "Mark Mimee provides information about companies and their progress in clinical trials, which supports the discussion."
        }
    },
    {
        "utterance": "Jae Sung: Got it. It's it's happening is the short answer. Got it. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a simple acknowledgment without adding new content or context."
        }
    },
    {
        "utterance": "Jae Sung: What disease though? ",
        "annotations": {
            "Ask Question": "Jae Sung is requesting information about the specific disease being referred to in the context of engineering bugs for clinical trials."
        }
    },
    {
        "utterance": "Mark Mimee: Uh so that was the I think that was the PKU example. Um I think they also had a phase one ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Mark Mimee: uh thing for hyperammonemia that uh wasn't as positive so they're going forward with PKU. And now them as well as almost everyone else is going after cancer immunotherapy as well. trying to use those as to modulate the the the utility of those drugs. So I think those I mean those pertain to this, but you know, a lot of people are thinking about that. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by discussing ongoing research and applications.",
            "supportive response": "The speaker provides a positive evaluation of the ongoing research directions.",
            "clarify goal": "The speaker discusses the goals and directions of research, providing clarity on current focuses.",
            "summarize conversation": "The speaker summarizes the direction of research, highlighting areas of focus."
        }
    },
    {
        "utterance": "Jae Sung: How do you get those bugs out? ",
        "annotations": {
            "ask question": "The speaker is requesting information about the process of eliminating or controlling engineered microbes."
        }
    },
    {
        "utterance": "Jae Sung: After after the job's done. ",
        "annotations": {
            "process management": "The speaker is inquiring about the process of stopping or removing the microbes after they have completed their task, indicating a concern for managing the outcome of a biotherapeutic approach."
        }
    },
    {
        "utterance": "Mark Mimee: Yeah, oh so most of them are engineered with auxotrophies so that they're like only uh by the time they're excreted, they're already dead is the way that these things are. So none of these applications are of like trying to colonize a host for months on end and for them to dynamically respond. They're mostly just using the bugs as like bags to carry enzymes or some relatively complex system so that I can carry out an activity and then sort of self-destruct by the time they leave. ",
        "annotations": {
            "develop idea": "The speaker expands on existing ideas by explaining how microbes are engineered with auxotrophies for specific applications.",
            "signal expertise": "The speaker demonstrates expertise in microbial engineering by providing detailed information about the engineering process and goals."
        }
    },
    {
        "utterance": "Jae Sung: I see. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Mark Mimee: But they could always evolve uh ways around these kill switches. ",
        "annotations": {
            "Critical response": "Mark Mimee is questioning the effectiveness of kill switches by pointing out a potential flaw.",
            "Offer feedback": "He is providing a specific consideration for the design or implementation of kill switches in engineered organisms."
        }
    },
    {
        "utterance": "Mark Mimee: That's where a good deal of the concern is. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges a concern raised, showing engagement with the discussion."
        }
    },
    {
        "utterance": "Will Ludington: Yeah, do people look at the I mean the temperature is a major factor in terms of uh how well something can deal with an auxotrophy. Um so and often times like lower temperature makes things more tolerant. Um is that like in in that field? Is that a uh I mean there I assume they're engineer at 37 degrees but then they get on the environment and they're at, you know, significantly less than 37 degrees. ",
        "annotations": {
            "ask question": "The speaker is asking for information or clarification on how temperature affects auxotrophy in engineered bacteria, indicating a request for knowledge or expertise."
        }
    },
    {
        "utterance": "Mark Mimee: Yeah, and I know like even um there's like some stuff out of Pen Silver's group which was using that temperature differential as an indicator that a bacteria is escaping the body and therefore should self-destruct. So could kind of detect that it wasn't room temperature, it's ingested, goes up to 37 at that point it turns on its therapeutic capabilities and then when it goes back out the other end and it drops back down to room temperature so that's when it's going to initiate the whole self-destruct mechanism. ",
        "annotations": {
            "Develop idea": "The speaker is elaborating on the concept of using temperature differentials to control the activity of engineered bacteria for therapeutic purposes.",
            "Supportive response": "The utterance provides additional information and insights into the application of engineered bacteria.",
            "Offer feedback": "The speaker discusses a specific example of how engineered bacteria can be designed to self-destruct based on temperature changes."
        }
    },
    {
        "utterance": "Mark Mimee: At least some people are thinking about that. ",
        "annotations": {
            "Supportive response": "Mark Mimee is expressing agreement or acknowledgment of the considerations discussed."
        }
    },
    {
        "utterance": "Mark Mimee: We don't work on that. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: We have uh about a minute left. Lisa, how are you doing with that? Uh it is messaged Elizabeth. It's uh done and she's taken a look at it now to see make sure she knows what she wants to say, I think. Yes. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by mentioning they have about a minute left.",
            "ask question": "The speaker asks Lisa about her progress with 'Lisa, how are you doing with that?'",
            "encourage participation": "By asking Lisa about her progress, the speaker is encouraging her to contribute or participate in the discussion."
        }
    },
    {
        "utterance": "Lisa Osborne: Yeah, Lisa did a really nice job organizing all of those like everyone's thoughts. It looks really nice. ",
        "annotations": {
            "Supportive Response": "The speaker is expressing agreement and positive evaluation for someone's effort in organizing discussion points."
        }
    },
    {
        "utterance": "Lisa Osborne: This was a really like I'm sorry that I didn't have much to add uh listening to you guys, but so much fun to think about and this this particular conversation seemed like the one that really uncovered like we don't know what we're doing. Like there is so much. Like it seemed like every other conversation that was in there was like, you know, like everybody's got their own bits of expertise and areas that they're looking at, but this is just black boxish is fun. ",
        "annotations": {
            "identify gap": "Lisa explicitly recognizes the gaps in knowledge discussed during the conversation.",
            "supportive response": "Lisa expresses a positive and supportive tone towards the conversation.",
            "express humor": "Lisa uses humor to describe the conversation as 'black boxish is fun'."
        }
    },
    {
        "utterance": "Jae Sung: I I really like this type of, you know, conference. It's like everybody just gets together from various domains and just talk and just, you know, a nice theme comes out just organically. You know, rather than the conferences we're used to, we just listen and just listen to talks, you know, talk by talk by talk and hopefully get to ask questions, but this was really fun and very good creative exercise. Um, thanks for all the facilitators, Emily and Rosa for uh, you know, helping us with organize everything. ",
        "annotations": {
            "supportive response": "The speaker expresses agreement and positive evaluation for the conference format and thanks the facilitators, showing support and appreciation."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Uh we're going to close in 30 seconds. I don't see the update yet on the slides. Um so I don't know if Lisa or Elizabeth is going to put it up. ",
        "annotations": {
            "process management": "Rosa Krajmalnik-Brown is managing the meeting flow by announcing the closure time and inquiring about slide updates."
        }
    },
    {
        "utterance": "Elizabeth Bess: Um I think I see it. Uh maybe I'm looking at the wrong spot though. I see 3.1 key points. Is that the right spot? ",
        "annotations": {
            "ask question": "Elizabeth Bess is seeking confirmation on whether she is looking at the correct section.",
            "process management": "She is trying to navigate and understand the content being discussed or presented."
        }
    },
    {
        "utterance": "Lisa Osborne: I hope so. That's where I put it. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Elizabeth Bess: Okay, I see it. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Elizabeth Bess: I see it too. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it's a brief acknowledgment"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Okay. Thanks everyone. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Elizabeth Bess: Thanks. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    }
]